AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
AN2 Therapeutics appointed Cameron Trenor, M.D. as Chief Medical Officer, bringing over two decades of experience in clinical development for rare diseases, hematology, and oncology. Dr. Trenor most recently served as CMO at Cellarity and succeeds Dr.
Key figures
- Active phase 2 studies expected 2026
- 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.